Press releases

13 Oct 2025

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

9 Oct 2025

Transparency notification FMR LLC

18 Sep 2025

UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV

17 Sep 2025

BIMZELX[®]▼(bimekizumab) new three-year data in hidradenitis suppurativa at EADV showed sustained disease control across the most stringent clinical endpoints

17 Sep 2025

BIMZELX[®][▼] (bimekizumab) data in moderate-to-severe plaque psoriasis at EADV showed four-year sustained remission, and potential to reduce psoriatic arthritis progression risk

29 Aug 2025

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Press releases

Press releases

Search Press releases

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Transparency notification FMR LLC

UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV

BIMZELX[®]▼(bimekizumab) new three-year data in hidradenitis suppurativa at EADV showed sustained disease control across the most stringent clinical endpoints

BIMZELX[®][▼] (bimekizumab) data in moderate-to-severe plaque psoriasis at EADV showed four-year sustained remission, and potential to reduce psoriatic arthritis progression risk

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)

Transparency notification FMR LLC

UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV

BIMZELX[®]▼(bimekizumab) new three-year data in hidradenitis suppurativa at EADV showed sustained disease control across the most stringent clinical endpoints

BIMZELX[®][▼] (bimekizumab) data in moderate-to-severe plaque psoriasis at EADV showed four-year sustained remission, and potential to reduce psoriatic arthritis progression risk

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Choose a Country